八种喹诺酮类药物对脆弱拟杆菌群成员的比较活性
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.
作者信息
Borobio M V, Conejo M, Ramirez E, Suarez A I, Perea E J
机构信息
Department of Microbiology, University of Seville.
出版信息
Antimicrob Agents Chemother. 1994 Jun;38(6):1442-5. doi: 10.1128/AAC.38.6.1442.
Abstract
The in vitro activities of five new quinolones (clinafloxacin [CI-960 or PD-127391], BAY Y 3118, E-4868, E-5065, and E-5068) against 100 Bacteroides fragilis group bacterial isolates were compared with those of ciprofloxacin, ofloxacin, and sparfloxacin. Overall, E-5068 was the most active in vitro (MIC for 90% of isolates tested [MIC90], 0.25 microgram/ml); this was followed by clinafloxacin and BAY Y 3118 (MIC90, 0.5 microgram/ml). Ciprofloxacin, sparfloxacin, and ofloxacin were the least active (MIC90s, 64, 16, and 16 micrograms/ml, respectively). B. fragilis and Bacteroides caccae were more susceptible than the other members of the B. fragilis group to all of the quinolones tested.
摘要
比较了五种新型喹诺酮类药物（克林沙星[CI-960或PD-127391]、BAY Y 3118、E-4868、E-5065和E-5068）对100株脆弱拟杆菌属细菌分离株的体外活性，并与环丙沙星、氧氟沙星和司帕沙星进行了比较。总体而言，E-5068的体外活性最强（90%受试分离株的最低抑菌浓度[MIC90]为0.25微克/毫升）；其次是克林沙星和BAY Y 3118（MIC90为0.5微克/毫升）。环丙沙星、司帕沙星和氧氟沙星的活性最低（MIC90分别为64、16和16微克/毫升）。脆弱拟杆菌和粪拟杆菌比脆弱拟杆菌属的其他成员对所有测试的喹诺酮类药物更敏感。
相似文献
1
Comparative activities of eight quinolones against members of the Bacteroides fragilis group.八种喹诺酮类药物对脆弱拟杆菌群成员的比较活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1442-5. doi: 10.1128/AAC.38.6.1442.
2
Comparative in vitro activities of new quinolones against coryneform bacteria.新型喹诺酮类药物对棒状杆菌的体外活性比较
Antimicrob Agents Chemother. 1994 Jun;38(6):1439-41. doi: 10.1128/AAC.38.6.1439.
3
Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.环丙沙星、氧氟沙星、司帕沙星、替马沙星、CI-960、CI-990和WIN 57273对厌氧菌的比较活性。
Antimicrob Agents Chemother. 1992 May;36(5):1158-62. doi: 10.1128/AAC.36.5.1158.
4
In-vitro activity of four new fluoroquinolones.四种新型氟喹诺酮类药物的体外活性
J Antimicrob Chemother. 1994 Jul;34(1):53-64. doi: 10.1093/jac/34.1.53.
5
Susceptibilities of 123 Xanthomonas maltophilia strains to clinafloxacin, PD 131628, PD 138312, PD 140248, ciprofloxacin, and ofloxacin.123株嗜麦芽窄食单胞菌对克林沙星、PD 131628、PD 138312、PD 140248、环丙沙星和氧氟沙星的敏感性。
Antimicrob Agents Chemother. 1994 Feb;38(2):369-70. doi: 10.1128/AAC.38.2.369.
6
In vitro antimicrobial activity of sparfloxacin (AT-4140, CI-978, PD 131501) compared with numerous other quinolone compounds.与众多其他喹诺酮类化合物相比，司帕沙星（AT - 4140、CI - 978、PD 131501）的体外抗菌活性。
Diagn Microbiol Infect Dis. 1991 Jul-Aug;14(4):319-30. doi: 10.1016/0732-8893(91)90023-9.
7
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.司帕沙星暴露后脆弱拟杆菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
8
gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.脆弱拟杆菌群菌株中与喹诺酮耐药性相关的gyrA突变。
Antimicrob Agents Chemother. 2001 Jul;45(7):1977-81. doi: 10.1128/AAC.45.7.1977-1981.2001.
9
In vivo efficacies of quinolones and clindamycin for treatment of infections with Bacteroides fragilis and/or Escherichia coli in mice: correlation with in vitro susceptibilities.喹诺酮类药物和克林霉素对小鼠体内脆弱拟杆菌和/或大肠杆菌感染的治疗效果：与体外药敏性的相关性
Antimicrob Agents Chemother. 1993 May;37(5):997-1000. doi: 10.1128/AAC.37.5.997.
10
In vitro activity of BAY 12-8039, a new fluoroquinolone.新型氟喹诺酮类药物BAY 12 - 8039的体外活性
Antimicrob Agents Chemother. 1997 Jan;41(1):101-6. doi: 10.1128/AAC.41.1.101.
引用本文的文献
1
Common Oral Medications Lead to Prophage Induction in Bacterial Isolates from the Human Gut.常见的口服药物会诱导人体肠道分离菌中的噬菌体的产生。
Viruses. 2021 Mar 11;13(3):455. doi: 10.3390/v13030455.
2
In vitro activities of newer quinolones against bacteroides group organisms.新型喹诺酮类药物对拟杆菌属微生物的体外活性。
Antimicrob Agents Chemother. 2002 Oct;46(10):3276-9. doi: 10.1128/AAC.46.10.3276-3279.2002.
3
Fluoroquinolone resistance in Bacteroides fragilis following sparfloxacin exposure.司帕沙星暴露后脆弱拟杆菌对氟喹诺酮类药物的耐药性
Antimicrob Agents Chemother. 1999 Sep;43(9):2251-5. doi: 10.1128/AAC.43.9.2251.
4
Use of newer quinolones for the treatment of intraabdominal infections: focus on clinafloxacin.新型喹诺酮类药物在腹腔内感染治疗中的应用：聚焦于克林沙星
Infection. 1999 May-Jun;27(3):166-72. doi: 10.1007/BF02561522.
5
In vitro activities of Y-688, a new 7-substituted fluoroquinolone, against anaerobic bacteria.新型7-取代氟喹诺酮类药物Y-688对厌氧菌的体外活性
Antimicrob Agents Chemother. 1998 Feb;42(2):419-24. doi: 10.1128/AAC.42.2.419.
本文引用的文献
1
Methods for testing the susceptibility of anaerobic bacteria to two fluoroquinolone compounds, PD 131628 and clinafloxacin.测试厌氧细菌对两种氟喹诺酮类化合物（PD 131628和克林沙星）敏感性的方法。
J Antimicrob Chemother. 1993 Jun;31(6):893-900. doi: 10.1093/jac/31.6.893.
2
In vitro activity of E-4868, a new trifluoroquinolone, compared to six similar compounds.新型三氟喹诺酮类药物E-4868与六种类似化合物的体外活性比较。
Eur J Clin Microbiol Infect Dis. 1993 Feb;12(2):134-41. doi: 10.1007/BF01967592.
3
In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.新型喹诺酮BAY y 3118对厌氧菌的体外活性
Eur J Clin Microbiol Infect Dis. 1993 Aug;12(8):640-2. doi: 10.1007/BF01973648.
4
Comparative in-vitro activities of the new quinolone, Bay y 3118, and ciprofloxacin, sparfloxacin, tosufloxacin, CI-960 and CI-990.新型喹诺酮类药物Bay y 3118与环丙沙星、司帕沙星、妥舒沙星、CI-960和CI-990的体外活性比较
J Antimicrob Chemother. 1993 Apr;31(4):505-22. doi: 10.1093/jac/31.4.505.
5
Effect of inoculum, pH, and medium on the activity of ciprofloxacin against anaerobic bacteria.接种量、pH值和培养基对环丙沙星抗厌氧菌活性的影响。
Antimicrob Agents Chemother. 1984 Mar;25(3):342-3. doi: 10.1128/AAC.25.3.342.
6
In vitro antibacterial activity of AM-715, a new nalidixic acid analog.新型萘啶酸类似物AM - 715的体外抗菌活性
Antimicrob Agents Chemother. 1980 Feb;17(2):103-8. doi: 10.1128/AAC.17.2.103.
7
Comparative activity of the quinolones against anaerobic bacteria isolated at community hospitals.喹诺酮类药物对社区医院分离出的厌氧菌的比较活性。
Antimicrob Agents Chemother. 1985 Apr;27(4):657-9. doi: 10.1128/AAC.27.4.657.
8
Symposium on antimicrobial agents. The quinolones.
Mayo Clin Proc. 1987 Nov;62(11):1007-12. doi: 10.1016/s0025-6196(12)65073-3.
9
The in-vitro activity of PD127,391, a new quinolone.新型喹诺酮类药物PD127,391的体外活性
J Antimicrob Chemother. 1988 Aug;22(2):135-41. doi: 10.1093/jac/22.2.135.
10
Evolution of antimicrobial susceptibility in isolates of the Bacteroides fragilis group in Spain.西班牙脆弱拟杆菌群菌株的抗菌药物敏感性演变
Rev Infect Dis. 1990 Jan-Feb;12 Suppl 2:S142-51. doi: 10.1093/clinids/12.supplement_2.s142.
Zotero 插件